We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

New Rapid Test Determines Amount of Neutralizing Antibodies Against SARS-CoV-2 Within Short Period of Time

By HospiMedica International staff writers
Posted on 03 Aug 2020
Print article
Image: New Rapid Test Determines Amount of Neutralizing Antibodies Against SARS-CoV-2 Within Short Period of Time (Photo courtesy of FSVO/Renate Boss)
Image: New Rapid Test Determines Amount of Neutralizing Antibodies Against SARS-CoV-2 Within Short Period of Time (Photo courtesy of FSVO/Renate Boss)
A Swiss-German team of researchers have developed a test that determines the amount of neutralizing antibodies against SARS-CoV-2 within a short period of time.

The test was developed at the Institute of Virology and Immunology (IVI) of the University of Bern (Bern, Switzerland) and the Swiss Federal Office for Food Safety and Animal Health (Köniz, Switzerland), and evaluated by the Ruhr-University Bochum (RUB Bochum, Germany) using serum samples from COVID-19 patients.

To determine immunity to SARS-CoV-2 and the effectiveness of potential vaccines, the amount of neutralizing antibodies in the blood of recovered or vaccinated individuals must be determined. A traditional neutralization test usually takes two to three days and must be carried out with infectious coronaviruses in a laboratory complying with biosafety level 3. The new test launched by the team of Swiss-German researchers takes only 18 hours and does not have high biosafety requirements.

In order to detect antibodies against SARS-CoV-2, the researchers used another virus that does not propagate and exchanged the envelope protein of this virus for the spike protein of the novel coronavirus, which mediates virus entry and infection. As a result, the viruses can be identified by antibodies against SARS-CoV-2 that bind to the viruses which have been altered in this way and neutralize them so that they can no longer penetrate the host cells. Since the virus pseudotyped in this way cannot propagate in host cells, no elaborate biosafety precautions are necessary for the test.

In order to determine the amount of antibodies, the researchers genetically modified the virus so that green fluorescent protein and luciferase, an enzyme from fireflies, will be produced by the infected cells. The green fluorescence is an indicator of infection with the pseudotyped virus. The less green cells found, the more neutralizing antibodies are present which block the virus. In addition, a luminometer can be used to read the luminescence signal produced by the luciferase enzyme – another way of evaluating the test.

In order to check the reliability and comparability with the conventional neutralization test, the researchers applied it to blood samples from COVID-19 patients. The direct comparison showed a good correlation between the two test systems. As compared to 56 hours for the conventional test, the new test is much faster, with only 18 hours to test results.

Related Links:
University of Bern
Swiss Federal Office for Food Safety and Animal Health
Ruhr-University Bochum


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Enterprise Imaging & Reporting Solution
Syngo Carbon

Print article

Channels

Critical Care

view channel
Image: A machine learning tool can identify patients with rare, undiagnosed diseases years earlier (Photo courtesy of 123RF)

Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs

Patients suffering from rare diseases often endure extensive delays in receiving accurate diagnoses and treatments, which can lead to unnecessary tests, worsening health, psychological strain, and significant... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more